Shares of Horizon Discovery Group PLC (LON:HZD) have been given a consensus rating of “Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is GBX 240 ($3.25).
Several research firms have recently weighed in on HZD. Numis Securities reaffirmed a “buy” rating and issued a GBX 300 ($4.07) price target on shares of Horizon Discovery Group in a report on Friday, December 29th. N+1 Singer upped their price target on shares of Horizon Discovery Group from GBX 219 ($2.97) to GBX 250 ($3.39) and gave the stock a “buy” rating in a report on Friday, September 22nd.
Shares of Horizon Discovery Group (LON HZD) opened at GBX 215 ($2.92) on Thursday. The stock has a market cap of $320.54 and a price-to-earnings ratio of -1,535.71. Horizon Discovery Group has a 1-year low of GBX 160 ($2.17) and a 1-year high of GBX 294 ($3.99).
Horizon Discovery Group Company Profile
Horizon Discovery Group plc is a United Kingdom-based life science company. The Company uses gene editing and gene modulation application. Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer.
Receive News & Ratings for Horizon Discovery Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group and related companies with MarketBeat.com's FREE daily email newsletter.